AstraZeneca plc (LON:AZN) had its price target boosted by Jefferies Group from GBX 5,800 ($71.78) to GBX 6,000 ($74.26) in a research note released on Thursday morning. Jefferies Group currently has a buy rating on the biopharmaceutical company’s stock.
Several other research firms have also issued reports on AZN. Shore Capital reaffirmed a hold rating on shares of AstraZeneca plc in a research report on Thursday, June 23rd. Credit Suisse Group AG reissued an underperform rating and issued a GBX 4,000 ($49.50) price objective on shares of AstraZeneca plc in a research report on Wednesday, July 13th. Citigroup Inc. reissued a buy rating on shares of AstraZeneca plc in a research report on Friday, September 23rd. Goldman Sachs Group Inc. set a GBX 4,000 ($49.50) price objective on shares of AstraZeneca plc and gave the company a sell rating in a research report on Wednesday, June 29th. Finally, JPMorgan Chase & Co. restated a neutral rating and issued a GBX 4,900 ($60.64) price target on shares of AstraZeneca plc in a research note on Tuesday, August 23rd. Five equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. AstraZeneca plc currently has an average rating of Hold and an average price target of GBX 4,960.13 ($61.39).
AstraZeneca plc (LON:AZN) traded down 0.18% during mid-day trading on Thursday, reaching GBX 4941.50. 918,871 shares of the company’s stock traded hands. The firm has a 50 day moving average of GBX 4,998.32 and a 200 day moving average of GBX 4,469.91. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00. The firm’s market cap is GBX 62.51 billion.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.